RxDoctor Payments DataLook up a doctor →

David Stewart, MD

Interventional Cardiology · Chicago, ILNPI 1700042389

Payments from drug & device makers

$240,671in general payments, 2019–2025

Across 1,044 payments — averaging $230.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$127K
  • Cardiovascular Systems Inc.$45K
  • Philips North America LLC$30K
  • Abbott$7K
  • Edwards Lifesciences$5K
  • Inari Medical, Inc.$5K
  • plus $21K from 51 others

What the payments were for

  • Consulting fees$4,0002%
  • Speaking & faculty fees$101,85560%
  • Travel & lodging$29,05117%
  • Food & beverage$34,39720%
  • Entertainment$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$240,671 in reported general payments places this provider in the 90th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$653,582
Medicare patients
1,677
Services billed
6,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban603$767,879
XareltoRivaroxaban267$336,158
EntrestoSacubitril/Valsartan206$304,464
Repatha SureclickEvolocumab159$144,951
BrilintaTicagrelor119$84,243
FarxigaDapagliflozin Propanediol50$54,598
Praluent PenAlirocumab54$41,051
JardianceEmpagliflozin15$19,933
Metoprolol Succinate1,191$13,656
VascepaIcosapent Ethyl20$12,305
ClopidogrelClopidogrel Bisulfate1,094$10,177
Clonidine72$9,724
Atorvastatin Calcium1,215$8,879
Midodrine Hcl54$7,128
Bumetanide200$5,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$767,879603 claims
Johnson & JohnsonXarelto$510$336,158267 claims
NovartisEntresto$2,098$304,464206 claims
AstraZenecaBrilinta, Farxiga$348$138,841169 claims
Boehringer IngelheimJardiance$124$19,93315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →